225 related articles for article (PubMed ID: 17404367)
1. Breast cancer mortality trends in the United States according to estrogen receptor status and age at diagnosis.
Jatoi I; Chen BE; Anderson WF; Rosenberg PS
J Clin Oncol; 2007 May; 25(13):1683-90. PubMed ID: 17404367
[TBL] [Abstract][Full Text] [Related]
2. Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer.
Anderson WF; Chen BE; Jatoi I; Rosenberg PS
Breast Cancer Res Treat; 2006 Nov; 100(1):121-6. PubMed ID: 16685588
[TBL] [Abstract][Full Text] [Related]
3. Dissemination of adjuvant multiagent chemotherapy and tamoxifen for breast cancer in the United States using estrogen receptor information: 1975-1999.
Mariotto AB; Feuer EJ; Harlan LC; Abrams J
J Natl Cancer Inst Monogr; 2006; (36):7-15. PubMed ID: 17032888
[TBL] [Abstract][Full Text] [Related]
4. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
Yu KD; Wu J; Shen ZZ; Shao ZM
J Clin Endocrinol Metab; 2012 Dec; 97(12):E2201-9. PubMed ID: 22993034
[TBL] [Abstract][Full Text] [Related]
5. Radiation therapy use and outcomes among older women with ER-positive and ER-negative stage I breast cancer.
Shen X; Anne PR; Keith SW; Wojcieszynski A; Mishra MV; Bar-Ad V; Showalter TN
Am J Clin Oncol; 2014 Jun; 37(3):241-7. PubMed ID: 23241502
[TBL] [Abstract][Full Text] [Related]
6. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women.
Jemal A; Ward E; Thun MJ
Breast Cancer Res; 2007; 9(3):R28. PubMed ID: 17477859
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
Weiss A; Noorbakhsh A; Tokin C; Chang D; Blair SL
Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
[TBL] [Abstract][Full Text] [Related]
8. The prognostic effect of estrogen receptor status differs for younger versus older breast cancer patients.
Sopik V; Sun P; Narod SA
Breast Cancer Res Treat; 2017 Sep; 165(2):391-402. PubMed ID: 28601929
[TBL] [Abstract][Full Text] [Related]
9. A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.
Munoz DF; Xu C; Plevritis SK
Med Decis Making; 2018 Apr; 38(1_suppl):89S-98S. PubMed ID: 29554473
[TBL] [Abstract][Full Text] [Related]
10. Is there a cause-specific survival benefit of postmastectomy radiation therapy in women younger than age 50 with T3N0 invasive breast cancer? A SEER database analysis: outcomes by receptor status/race/age: analysis using the NCI Surveillance, Epidemiology, and End Results (SEER) database.
Yan W; Christos P; Nori D; Chao KS; Ravi A
Am J Clin Oncol; 2013 Dec; 36(6):552-7. PubMed ID: 22868241
[TBL] [Abstract][Full Text] [Related]
11. Time-trends in survival in young women with breast cancer in a SEER population-based study.
Ademuyiwa FO; Groman A; Hong CC; Miller A; Kumar S; Levine E; Erwin D; Ambrosone C
Breast Cancer Res Treat; 2013 Feb; 138(1):241-8. PubMed ID: 23371505
[TBL] [Abstract][Full Text] [Related]
12. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
[TBL] [Abstract][Full Text] [Related]
13. Contralateral prophylactic mastectomy provides no survival benefit in young women with estrogen receptor-negative breast cancer.
Pesce C; Liederbach E; Wang C; Lapin B; Winchester DJ; Yao K
Ann Surg Oncol; 2014 Oct; 21(10):3231-9. PubMed ID: 25081341
[TBL] [Abstract][Full Text] [Related]
14. Body weight correlates with mortality in early-stage breast cancer.
Enger SM; Greif JM; Polikoff J; Press M
Arch Surg; 2004 Sep; 139(9):954-58; discussion 958-60. PubMed ID: 15381612
[TBL] [Abstract][Full Text] [Related]
15. Use and outcomes of adjuvant chemotherapy in older women with breast cancer.
Giordano SH; Duan Z; Kuo YF; Hortobagyi GN; Goodwin JS
J Clin Oncol; 2006 Jun; 24(18):2750-6. PubMed ID: 16782915
[TBL] [Abstract][Full Text] [Related]
16. Distinct breast cancer incidence and prognostic patterns in the NCI's SEER program: suggesting a possible link between etiology and outcome.
Anderson WF; Jatoi I; Devesa SS
Breast Cancer Res Treat; 2005 Mar; 90(2):127-37. PubMed ID: 15803359
[TBL] [Abstract][Full Text] [Related]
17. Community-based use of chemotherapy and hormonal therapy for early-stage breast cancer: 1987-2000.
Harlan LC; Clegg LX; Abrams J; Stevens JL; Ballard-Barbash R
J Clin Oncol; 2006 Feb; 24(6):872-7. PubMed ID: 16484696
[TBL] [Abstract][Full Text] [Related]
18. Underlying causes of the black-white racial disparity in breast cancer mortality: a population-based analysis.
Menashe I; Anderson WF; Jatoi I; Rosenberg PS
J Natl Cancer Inst; 2009 Jul; 101(14):993-1000. PubMed ID: 19584327
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
Lancet; 1998 May; 351(9114):1451-67. PubMed ID: 9605801
[TBL] [Abstract][Full Text] [Related]
20. Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.
Jayasekara H; MacInnis RJ; Chamberlain JA; Dite GS; Leoce NM; Dowty JG; Bickerstaffe A; Win AK; Milne RL; Giles GG; Terry MB; Eccles DM; Southey MC; Hopper JL
Int J Cancer; 2019 Dec; 145(12):3207-3217. PubMed ID: 30771221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
